Week 2 - Dear Biotech - JPM Will Not Save You This Year…

Markets Continue to be Risk Off for 2022

Jan 14, 2022

∙ Paid

Hello Avatar! Welcome back for another week of biotech analysis. Today we focus on our weekly review of the public and private markets. Quick preview - it is UGLY. Sunday we are back with our weekly feature. This week will close out our review on Top Emerging Science Areas for 2022 with a deep dive on Innate Immune Modulators. Next week we aim to…

Keep reading with a 7-day free trial

Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.